Probiotics

Probiotics as adjuvant therapy in coeliac disease?

24 Apr 2014
BY Elena Verdú
In Autoimmune Diseases, Celiac Disease, Diet, Dysbiosis, Gut Microbiota, Probiotics, Research & Practice
2 Comments
0

At the occasion of the "New therapies in coeliac disease" conference hosted by Columbia University in New-York on March 20, 2014, Dr. Elena Verdú, our expert in Nutrition, is sharing with us the last trends in research in the field of Coeliac Disease (CeD), introducing the idea of a role of probiotics in the treatment of CeD. Presence of intestinal dysbiosis…

Elena Verdú
Dr. Verdu’s research has focused on the pathophysiology of inflammatory and functional gastrointestinal disorders. She undertook clinical research training at the University of Lausanne, Switzerland, where she studied the interaction between chronic infection with Helicobacter pylori and gastritis in humans and the possible therapeutic role of probiotic bacteria. Her PhD studies in the Institute of Microbiology and Gnotobiology at the Czech Academy of Science and University of Lausanne focused on the effect of bacterial antigens in animal models of inflammatory bowel disease. As a post-doctoral fellow at McMaster University she gained experience with animal models of gut functional diseases and investigated the mechanisms of action of probiotic bacteria. As a member of the Farncombe Family Digestive Health Research Institute at McMaster University, Dr. Verdu investigates host-microbial and dietary interactions in the context of celiac disease, irritable bowel syndrome and inflammatory bowel disease. She has been honored with the New Investigator Award (Canadian Celiac Association), the New Investigator Award (Functional Gut-Brain Research Group, USA) and the Campbell Research Award in celiac disease (Canadian Celiac Association). The American Gastroenterology Association and the Canadian Association of Gastroenterology have awarded her the “Master’s in Gastroenterology Award” for basic science and “Young Investigator’s Award”, respectively. She is Associate Professor at the Division of Gastroenterology, Dep. of Medicine at McMaster University and currently directs the Axenic Gnotobiotic Unit at McMaster.

Probiotics as adjuvant therapy in coeliac disease?

24 Apr 2014
BY Elena Verdú
In Autoimmune Diseases, Celiac Disease, Diet, Dysbiosis, Gut Microbiota, Probiotics, Research & Practice
2 Comments
0

At the occasion of the "New therapies in coeliac disease" conference hosted by Columbia University in New-York on March 20, 2014, Dr. Elena Verdú, our expert in Nutrition, is sharing with us the last trends in research in the field of Coeliac Disease (CeD), introducing the idea of a role of probiotics in the treatment of CeD. Presence of intestinal dysbiosis…

Elena Verdú
Dr. Verdu’s research has focused on the pathophysiology of inflammatory and functional gastrointestinal disorders. She undertook clinical research training at the University of Lausanne, Switzerland, where she studied the interaction between chronic infection with Helicobacter pylori and gastritis in humans and the possible therapeutic role of probiotic bacteria. Her PhD studies in the Institute of Microbiology and Gnotobiology at the Czech Academy of Science and University of Lausanne focused on the effect of bacterial antigens in animal models of inflammatory bowel disease. As a post-doctoral fellow at McMaster University she gained experience with animal models of gut functional diseases and investigated the mechanisms of action of probiotic bacteria. As a member of the Farncombe Family Digestive Health Research Institute at McMaster University, Dr. Verdu investigates host-microbial and dietary interactions in the context of celiac disease, irritable bowel syndrome and inflammatory bowel disease. She has been honored with the New Investigator Award (Canadian Celiac Association), the New Investigator Award (Functional Gut-Brain Research Group, USA) and the Campbell Research Award in celiac disease (Canadian Celiac Association). The American Gastroenterology Association and the Canadian Association of Gastroenterology have awarded her the “Master’s in Gastroenterology Award” for basic science and “Young Investigator’s Award”, respectively. She is Associate Professor at the Division of Gastroenterology, Dep. of Medicine at McMaster University and currently directs the Axenic Gnotobiotic Unit at McMaster.

[Press Release] Probiotics: First International Reference-Guide to Support Clinicians in the Management of Lower GI Symptoms

28 Oct 2013
BY GMFH Editing Team
In Guidelines, IBS, Probiotics, Research & Practice, Transit
No Comment
0

(Berlin, October 16, 2013) Clinicians with gastrointestinal (GI) patients often wish – and are asked by their patients – to recommend specific probiotics. However, a clear and accessible evidence-based reference guide on the role and effectiveness of specific probiotics and their clinical use for managing particular lower gastrointestinal problems has been lacking so far. Now a new reference guide, which…